CENPO Antibody

What is CENPO and what is its primary cellular function?

CENPO (Centromere protein O) is a component of the CENPA-CAD (nucleosome distal) complex that localizes at the centromere throughout the cell cycle. It plays crucial roles in the assembly of kinetochore proteins, mitotic progression, and chromosome segregation. CENPO facilitates the incorporation of newly synthesized CENPA into centromeres through its interaction with the CENPA-NAC complex and modulates kinetochore-bound levels of the NDC80 complex . As a member of the CENP-O class of proteins, it forms a stable complex with other centromere proteins and is required for proper kinetochore function and recovery from mitotic spindle damage .

What are the structural characteristics of CENPO protein?

CENPO is a protein with a calculated molecular weight of approximately 34 kDa, though its observed molecular weight in laboratory settings is also around 34 kDa. The protein exists in two isoforms with molecular weights of 33 and 34 kDa, and different lysates may bind to one or both isoforms in SDS-PAGE analyses. The full protein consists of approximately 300 amino acids . The immunogenic region used for antibody development is often a synthetic peptide from near the center of human CENPO, specifically within amino acids 170-220 .

How do CENPO antibodies differ from other anti-centromere antibodies?

CENPO antibodies specifically target the CENPO protein, whereas other anti-centromere antibodies (ACA) typically target CENP-A, CENP-B, and CENP-C, which are the major centromere components and main targets of ACA. CENPO is a component of the interphase centromere complex (ICEN) and is recognized by only a very minor population (approximately 3.5%) of ACA-positive patients with scleroderma, making anti-CENPO antibodies much rarer compared to other ACA . Unlike antibodies against CENP-A and CENP-B, which often coexist in patients with limited systemic sclerosis, anti-CENPO antibodies have not shown strong correlations with specific clinical features or other serological features .

What are the optimal methods for detecting CENPO using antibodies?

The optimal methods for detecting CENPO using antibodies include:

• Western Blot (WB): CENPO antibody can be used for detection at a concentration of 1-2 μg/mL. This technique has been validated in mouse tissue lysates, particularly kidney tissue .

• ELISA: This method provides high sensitivity for CENPO detection and has been validated for both research and diagnostic applications .

• Immunofluorescence: Used for visualizing the centromere localization of CENPO throughout the cell cycle.

When optimizing these techniques, researchers should consider that CENPO antibodies typically recognize two isoforms (33 and 34 kDa) in Western blots, and the protocol should be adjusted based on the specific tissue or cell line being used.

What validation criteria should be applied when using CENPO antibodies in research?

When validating CENPO antibodies for research, the following criteria should be applied:

• Specificity testing: Validate through multiple techniques (WB, ELISA, immunofluorescence) with known positive and negative controls.

• Cross-reactivity assessment: Evaluate potential cross-reactivity with other CENP family proteins. For instance, well-characterized CENPO antibodies are predicted not to cross-react with other members of the MTERFD protein family .

• Species reactivity validation: Confirm reactivity with samples from various species (human, mouse, rat) as needed for your research. Commercial CENPO antibodies such as A11021 have been tested and confirmed to react with human, mouse, and rat samples .

• Molecular weight verification: Confirm detection at the expected molecular weight (34 kDa observed, 33.8 kDa calculated) .

• Peptide blocking: For polyclonal antibodies, peptide competition assays can be performed using the immunogenic peptide to confirm specificity .

How should CENPO antibodies be stored and handled to maintain reactivity?

CENPO antibodies should be stored and handled according to the following guidelines to maintain optimal reactivity:

• Storage temperature: Can be stored at 4°C for three months or at -20°C for up to one year. Long-term storage should be at -20°C .

• Buffer composition: Typically supplied in PBS containing 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Avoid freeze-thaw cycles: Repeated freeze-thaw cycles should be avoided as they can degrade antibody quality and reduce reactivity .

• Temperature sensitivity: Antibodies should not be exposed to prolonged high temperatures .

• Aliquoting: For -20°C storage of larger volumes, aliquoting is recommended to prevent repeated freeze-thaw cycles, though some preparations specifically note that aliquoting is unnecessary .

• BSA addition: Some smaller volume preparations (e.g., 20 μl sizes) contain 0.1% BSA to help stabilize the antibody during storage .

What is the relationship between CENPO antibodies and autoimmune diseases?

CENPO antibodies have been identified in a small subset of patients with systemic autoimmune diseases, particularly those with anticentromere antibodies (ACA). Research indicates that:

• CENPO is targeted by sera from a very minor population (only 4 out of 114, or 3.5%) of ACA-positive patients with scleroderma .

• Unlike the more common anti-CENP-A and anti-CENP-B antibodies, which are found in approximately 48% of patients with limited systemic sclerosis (lSSc) and 9-11% of patients with diffuse systemic sclerosis (dSSc), anti-CENPO antibodies do not show clear associations with specific clinical features .

• In one documented case, a patient with a unique clinical course of scleroderma demonstrated markedly high reactivity to CENPO, suggesting potential clinical relevance in specific cases .

• Because CENPO is an ICEN (interphase centromere complex) component, this complex may represent a significant antigenic structure in systemic autoimmunity .

How do anti-CENPO antibodies compare with anti-CENP-A and anti-CENP-B antibodies in diagnostic value?

Anti-CENPO antibodies have significantly different diagnostic characteristics compared to the more common anti-CENP-A and anti-CENP-B antibodies:

Anti-CENP-A and anti-CENP-B antibodies show high disease specificity (93% and 96.5%, respectively) when comparing SSc patients to those with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) . In contrast, anti-CENPO antibodies are much rarer and have not been extensively studied for their diagnostic value .

Inhibition experiments with anti-CENP-A and anti-CENP-B antibodies have revealed no significant cross-reactivity between these antibodies, indicating they recognize distinct epitopes despite often occurring together in patients with limited SSc .

What experimental models have been developed to study the pathological effects of anti-centromere antibodies?

Several experimental models have been developed to study the pathological effects of anti-centromere antibodies, with important methodological considerations:

• Active immunization models: Studies have demonstrated that active immunization with centromere proteins like CENP-C can elicit autoantibodies in mice. For example, BALB/c mice immunized with human CENP-C in complete Freund's adjuvant (CFA) developed CENP-C antibodies that were detectable in both serum and oocytes .

• Reproductive impact models: Research has shown that CENP-C antibodies severely impair oocyte meiosis, providing a model for studying ACA's impact on fertility. In these models, mice immunized with CENP-C showed lower first polar body extrusion rates (indicating reduced oocyte maturation) and higher percentages of spindle defects (64.67±1.16% vs. 9.27±2.28% in control) and chromosome misalignment (50.80±2.40% vs. 8.30±1.16% in control) .

• Epitope spread models: Studies tracking the development of ACA responses have shown that initial autoimmunity against histones can lead to epitope spreading, resulting in a diverse anticentromere autoantibody repertoire. This model shows an ordered development of antibodies, first against histone regions of CENP-A, then against the N-terminus, followed by reactivity against CENP-B .

These models provide valuable frameworks for understanding the development of anti-centromere immune responses and their clinical consequences.

What is the significance of CENPO expression in cancer research?

CENPO expression has emerged as a significant area of interest in cancer research, particularly for its potential as a biomarker and therapeutic target:

These findings position CENPO as a promising biomarker and potential therapeutic target in cancer research, particularly in LUAD.

How does CENPO expression correlate with immune infiltration in cancer tissues?

CENPO expression demonstrates significant correlations with immune cell infiltration in cancer tissues, particularly in lung adenocarcinoma:

• Tumor microenvironment scores: Studies have shown that the StromalScore, ImmuneScore, and ESTIMATEScore are higher in CENPO low expression groups compared to CENPO high expression groups, suggesting that lower CENPO expression is associated with a more immunologically active tumor microenvironment .

• Specific immune cell correlations: CENPO expression in LUAD is significantly and positively correlated with multiple immune cell types, including:

  • Memory-activated CD4 T cells

  • Macrophages M0 and M1

  • CD8 T cells

  • Neutrophils

  • Naive B cells

  • Resting NK cells

  Conversely, CENPO expression is significantly negatively correlated with:

  • Resting mast cells

  • Resting dendritic cells

  • Memory B cells

  • Monocytes

  • Memory resting CD4 T cells

• Immune checkpoint correlations: CENPO expression shows significant positive correlations with immune checkpoint molecules including CD276, CD274, TNFSF4, TNFRSF9, and LAG3, while being negatively correlated with immune checkpoints such as LGALS9, TNFRSF14, CD40LG, and HHLA2 .

These correlations suggest that CENPO may influence the immune microenvironment of tumors and potentially affect response to immunotherapy.

What is the relationship between CENPO expression and drug sensitivity in cancer treatment?

Research has identified significant correlations between CENPO expression and sensitivity to various cancer therapeutics, with important implications for drug selection and treatment planning:

• Broad drug correlations: Analysis has shown that the IC50 (half maximal inhibitory concentration) of 114 drugs correlates with CENPO expression (P < 0.001), indicating that CENPO expression levels may predict response to a wide range of anticancer agents .

• Lung cancer-specific therapeutics: Among these drugs, 15 are clinically used lung cancer therapeutics, suggesting particular relevance for CENPO as a biomarker in lung cancer treatment strategies .

• Predictive biomarker potential: These findings support the potential use of CENPO as a biomarker for predicting drug therapy responses in LUAD, which could contribute to more personalized treatment approaches .

This relationship between CENPO expression and drug sensitivity highlights the potential utility of CENPO assessment in guiding treatment decisions and predicting therapy outcomes in cancer patients.

How can researchers distinguish between natural autoantibodies against CENPO and laboratory-generated antibodies in experimental settings?

Distinguishing between natural autoantibodies against CENPO and laboratory-generated antibodies requires a multifaceted approach:

• Epitope specificity analysis: Natural autoantibodies often target specific epitopes that differ from those recognized by laboratory-generated antibodies. For instance, autoantibodies against centromere proteins like CENP-A have been shown to target specific motifs (e.g., G-P-X1-R-X2) . Epitope mapping techniques, such as synthesizing peptides covering the complete CENPO amino acid sequence offset by 3 amino acids, can identify the specific regions targeted by antibodies .

• Isotype and subclass determination: Natural autoantibodies often have distinct isotype distributions compared to laboratory-generated antibodies. Immunoglobulin isotyping (IgG, IgM, IgA) and subclass determination can help differentiate their origin.

• Affinity measurements: Surface plasmon resonance (SPR) or bio-layer interferometry (BLI) can measure antibody-antigen binding kinetics. Natural autoantibodies typically have different affinity profiles compared to monoclonal antibodies raised in laboratory settings.

• Cross-reactivity profiling: Testing reactivity against related proteins or mimotopes. Natural autoantibodies may demonstrate cross-reactivity with homologous motifs on other autoantigens, whereas laboratory antibodies are typically more specific .

• Patient history and controls: For suspected natural autoantibodies, correlating with clinical features and testing control samples from healthy individuals can help establish their autoimmune nature.

What are the molecular mechanisms by which CENPO contributes to chromosome segregation and how can antibodies be used to study these functions?

The molecular mechanisms of CENPO in chromosome segregation can be studied using antibodies through several methodological approaches:

• Protein-protein interaction studies: CENPO functions as part of the CENPA-CAD complex and interacts with the CENPA-NAC complex to facilitate incorporation of newly synthesized CENPA into centromeres . Antibodies can be used in co-immunoprecipitation experiments to identify novel interaction partners or confirm known interactions.

• Chromatin immunoprecipitation (ChIP): CENPO antibodies can be used in ChIP experiments to identify genomic regions where CENPO is localized, providing insights into its role in centromere structure and function.

• Immunodepletion experiments: CENPO antibodies can be used to deplete the protein from cell extracts, followed by functional assays to assess the consequences on centromere assembly and function.

• Live-cell imaging: Fluorescently labeled CENPO antibody fragments (Fab) can be used to track CENPO dynamics during cell division without disrupting its function.

• Functional blocking studies: Microinjection of anti-CENPO antibodies into cells can disrupt CENPO function, revealing its role in kinetochore assembly and chromosome segregation. This approach is supported by studies showing that immunization with centromere proteins like CENP-C causes aberrant chromosome segregation during oocyte meiosis in mice .

• Super-resolution microscopy: Combined with specific antibodies, techniques like STORM or PALM can reveal the precise localization of CENPO within the three-dimensional structure of the centromere and kinetochore.

How might the development of anti-CENPO antibodies inform our understanding of autoimmune disease etiology and progression?

The development and study of anti-CENPO antibodies offer unique insights into autoimmune disease mechanisms:

• Epitope spreading mechanisms: Studies of anticentromere antibody development have shown that initial autoimmunity against histones can lead to epitope spreading, resulting in a diverse anticentromere antibody repertoire . For example, research tracking the development of ACA showed that initial reactivities were directed against core histones, followed by reactivity against CENP-A, and eventually CENP-B. This ordered development suggests a pattern of epitope spreading that may be general for anticentromere responses .

• Molecular mimicry assessment: Investigation of anti-CENPO antibodies can help determine whether they arise through molecular mimicry with infectious agents. Studies of other anticentromere antibodies have found that recognition of CENP-A motifs occurs earlier in development than antibody binding to Epstein-Barr nuclear antigen-1 (EBNA-1) motifs, suggesting that molecular mimicry from anti-viral responses is not the primary mechanism .

• Subclinical autoimmunity markers: Anti-CENPO antibodies have been detected in patients without clinical symptoms of autoimmune diseases, suggesting they may serve as early markers of subclinical autoimmunity or predisposition to certain autoimmune conditions.

• Pathogenic mechanisms: Experimental models showing that CENP antibodies can cause functional cellular defects (such as the aberrant chromosome segregation observed in mouse oocytes with anti-CENP-C antibodies) provide insights into how these antibodies might contribute to pathology even in the absence of clinical disease .

• Interphase centromere complex (ICEN) as an antigenic structure: The finding that CENPO, as a component of ICEN, can be targeted by autoantibodies suggests that the entire ICEN may be an important antigenic structure in systemic autoimmunity , pointing to potential targets for therapeutic intervention.

What are the technical challenges in developing highly specific monoclonal antibodies against CENPO and how might these be overcome?

Developing highly specific monoclonal antibodies against CENPO presents several technical challenges that can be addressed through advanced methodological approaches:

• Structural similarity challenges: CENPO shares structural features with other centromere proteins, potentially leading to cross-reactivity. This can be addressed by:

  • Selecting unique, non-conserved regions of CENPO for immunization

  • Using synthetic peptides from near the center of human CENPO (amino acids 170-220) as immunogens

  • Employing computational epitope prediction tools to identify CENPO-specific regions

• Conformational epitope preservation: CENPO's native conformation may contain important epitopes that are lost in denatured preparations. Solutions include:

  • Using native protein purification methods

  • Developing antibodies against properly folded recombinant CENPO

  • Screening antibodies against both native and denatured forms

• Limited immunogenicity: Some regions of CENPO may have limited immunogenicity due to evolutionary conservation. Strategies to overcome this include:

  • Coupling CENPO peptides to highly immunogenic carrier proteins

  • Using advanced adjuvant systems optimized for weak immunogens

  • Implementing DNA immunization approaches that can enhance immune responses

• Screening methodology optimization: To ensure specificity, implement rigorous screening:

  • Competitive ELISA with related centromere proteins

  • Western blotting against tissue lysates from CENPO knockout models

  • Super-resolution microscopy to confirm centromere localization

  • Immunoprecipitation followed by mass spectrometry to verify target specificity

• Species cross-reactivity considerations: For antibodies intended to recognize CENPO across species, target conserved regions while maintaining specificity:

  • Align CENPO sequences across species to identify conserved epitopes

  • Test candidate antibodies against cell lines from multiple species

  • Validate with tissue from conditional knockout models

By addressing these challenges through careful immunogen design, advanced screening methods, and rigorous validation, researchers can develop highly specific monoclonal antibodies against CENPO for a variety of research applications.